Targets › PD-L2
1 program from 1 company in 3 trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on PD-L2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Akeso | pulocimab (AK109) PD-L2 monoclonal antibody | PD-L2 | Phase 3 | Gastric and Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumor | Nov 2026 |
Gastric and Gastroesophageal Junction Adenocarcinoma (1) Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma (1) Advanced Solid Tumor (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.